Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
- Eisai's April-December Operating Profit Surges 28.4% on Lenvima, Guidance Lifted
February 3, 2020
- Asahi Kasei Expands License for iPS Cell-Derived Cartilage Products to Osteoarthritis, Meniscus Injury
February 3, 2020
- Sandoz Completes Aspen Japan Buyout
February 3, 2020
- ViiV Rolls Out HIV Doublet Dovato in Japan
February 3, 2020
- Sumitomo Dainippon’s April-December Sales Up 2.9% as Diabetes Meds Counter Off-Patent Dip
January 31, 2020
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Sumitomo Dainippon Starts Japan PI for AI-Designed Drug Candidate
January 31, 2020
- Evrenzo Filed for Anemia in Non-Dialysis CKD Patients in Japan: Astellas/FibroGen
January 31, 2020
- AstraZeneca Taps AI Chatbot to Answer Inquiries from Patient, Healthcare Providers
January 31, 2020
- Takeda Submits Cabozantinib in Japan for HCC, RCC OK Expected Soon
January 30, 2020
- Eisai Pairs Up with US Biotech on Liquid Biopsy-Based Genomic Profiling
January 30, 2020
- Novo’s Hemophilia A Med Esperoct Hits Shelves in Japan
January 30, 2020
- Chugai, UK Institutes Reach Settlement over Actemra Royalty Row
January 29, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- KM Biologics Teams Up with JB for Marketing of Globulin Product
January 28, 2020
- Otsuka’s Anti-CGRP Antibody Fremanezumab Smashes Primary Goals in Japan PII/III Studies for Migraine Prevention
January 28, 2020
- Xofluza Holds Top Spot in GP Promotion Ranking in December: Impact Track
January 27, 2020
- Opdivo Misses OS Goal in Platinum-Resistant Ovarian Cancer in PIII: Ono
January 27, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…